Importance Worldwide, 47 million people live with dementia and, by 2050, the number is
expected to increase to 131 million. Observations Dementia is an acquired loss of cognition …

Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …

Alzheimer's disease (AD) is the most frequent cause of cognitive impairment in middle-aged
and older populations. There is a lack of drugs that demonstrate significant efficacy in AD, so …

Cognitive impairment (CI) is one of the major clinical features of many neurodegenerative
diseases. It can be aging-related or even appear in non-central nerve system (CNS) …

Close to 6 million Americans have Alzheimer's disease (AD) or Alzheimer's disease and
related dementia (AD/ADRD). These high‐need, high‐cost patients are vulnerable to …

Neuroinflammation is a critical feature in the pathogenesis of neurodegenerative disorders
such as Alzheimer's disease (AD). Hesperetin can exert anti-inflammatory, antioxidant and …

Doxorubicin (DOX) causes deleterious cardiotoxicity. We aimed to investigate the protective
roles of metformin and donepezil against DOX-induced cardiotoxicity. In this randomized …

Background: Four prescription drugs (donepezil, galantamine, memantine, and rivastigmine)
are approved by the US FDA to treat symptoms of Alzheimer's disease (AD). Even modest …

Alzheimer's dementia (AD) is the most common major neurocognitive impairment and the
fifth leading cause of death in older adults in the United States. The diagnosis is clinical; …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex
etiology. The main neuropathological feature is the accumulation of amyloid-beta (Aβ), and …